AI-Driven Structural Insights into 11β-HSD1 Inhibition: Exploring Steroidal Pregnanes for Metabolic Disease Therapeutics
Type 2 diabetes mellitus (T2DM) remains a major global health challenge, with many patients failing to achieve optimal glycaemic control despite the availability of established therapies. The enzyme 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1), which catalyzes the local regeneration of active cortisol, represents a promising therapeutic target for addressing the multifactorial nature of metabolic disorders. This